علاج سرطان الغدد الليمفاوية هودجكين الكلاسيكي المبكر المناسب في البالغين مع معدل ترسيب الكريات أقل من 50 مم/ساعة وبدون مرض ضخم

References

• The NCCN Clinical Practice Guidelines look at the factors below to determine favorable (no risk factors) or unfavorable (one or more risk factors) for early-stage I-II HL: Bulky mediastinal disease or bulky disease greater than 10 cm, B symptoms (fever, night sweats, weight loss), Erythrocyte sedimentation rate (ESR) greater than 50 mm/hr, More than 3 nodal sites of disease.
• Having none of the risk factors listed below is considered favorable, whereas having one or more of the risk factors is considered unfavorable.
• The current treatment approach is to administer chemotherapy alone (without radiation therapy), or a combined modality therapy (combination chemotherapy followed by radiation therapy to areas of the body where lymphoma was found).
• For many years, ABVD has been the most commonly used chemotherapy regimen in adults for early-stage favorable HL.
• Current clinical practice guidelines for treatment of early-stage favorable HL suggest that at least 90 percent of patients can be cured with as few as two courses of ABVD followed by low-dose radiation therapy.
• Radiation can be used at the end of a chemotherapy regimen depending on how well the patient responded to the chemotherapy.
• A PET scan is typically performed after two cycles of therapy (interim PET) and at the end of therapy.
• A score of 1, 2 or 3 is considered negative, meaning there are no areas of concern.